Keywords
Factor-alpha.
Tuberculosis.
Incidence.
Autoimmune Diseases.
Arthritis, Rheumatoid.
Crohn Disease.
How to Cite
Abstract
Introduction: The anti-TNF drugs (inhibitors of tumor necrosis factor), used to treat autoimmune diseases, increased the risk of reactivating latent infections, especially tuberculosis and other bacterial and fungal infections. Objective: to determine the tuberculosis incidence in patients taking Anti-TNF drugs, from 2006 to 2010. Methods: A retrospective, descriptive study was conducted. From a list of APACs (Authorization for High-Complexity Procedures)from patients using anti-TNF, provided by the State Secretariat of Health -SP,we searched TBweb database ( Reporting and Monitoring System of Tuberculosis Cases), to identify possible cases of tuberculosis. The RecLink III software, which implements the technique of probabilistic record linkage, was used. Results: Of the 10,631 anti-TNF users 57 tuberculosis cases were identified and reported to TBweb, whose database contained 76,079 records. Patients with tuberculosis after Anti- TNF use were 40, resulting in an incidence rate of 375.5 cases/100,000 patients taking the drug; 9.6 times higher than the general population, 39.2 cases/100,000 inhabitants. Conclusion: Despite the limitations of the study, arising from the fact of working with secondary data, there was an increase in the incidence of tuberculosis among patients undergoing treatment with Anti-TNF drugs, justifying the adoption of strategies for the prevention and monitoring of tuberculosis in patients treated with these drugs.
References
Farga V, Caminero JA. Tuberculosis. In: Farga V, Caminero JA. Historia Natural de la tuberculosis en el ser humano. Etiopatogenia. Santiago de Chile: Editorial Mediterráneo. 2011; p. 27-44.
Andrade Junior DR, Santos AS, Castro I, Andrade DR. Correlation between serum tumor necrosis factor alpha levels and clinical severity of tuberculosis. Braz J Infect Dis. 2008;12(3):226-33
Vitale RF, Ribeiro FAQ. O papel do fator de necrose tumoral alfa (TNF-α) no processo de erosão óssea presente no colesteatoma adquirido da orelha média. Rev Bras Otorrinolaringol. 2007;73(1):123-7.
Wallis R. Infectious complications of tumor necrosis factor blockade. Curr Opin Infect Dis. 2009; 22: 403-9.
Schachna L. The anti-TNF revolution in ankylosing spondylitis. Med J Aust. 2004;181(10):529-30.
Bray M G, Poulain C, Dougados M, Gossec L. Frequency and tolerance of antituberculosis treatment according to national guidelines for prevention of risk of tuberculosis due to tumor necrosis fator blocker treatment. Joint Bone Spine. 2010;77(2):135-41.
Pereira I A et al. Consenso 2012 da Sociedade Brasileira de Reumatologia para o tratamento da artrite reumatoide. Rev Bras Reumatol. 2012; 52(2): 135-74.
Silva LC1, Geluk A, Arnone M, Romiti R, Franken KC, Duarte AJ, Takahashi MD, Benard G. Infliximab partially impairs the anti-Mycobacterium tuberculosis immune responses of severe psoriasis patients with positive tuberculin skin-test. J Eur Acad Dermatol Venereol. 2012;26(3):319-24.
Miller EA, Ernst JD. Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed. J Clin Invest. 2009;119(5): 1079-82.
Gómez-Reino JJ, Carmona L, Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis fator antagonists due to incomplete prevention of reactivation of latente infection. Arthritis Rheum. 2007; 57(5): 756-61.
Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immunemediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol. 2009; 22(3): 557-65.
Camargo Jr KR.; Coeli CM. Reclink: Aplicativo para o relacionamento de banco de dados implementando o método probabilistic record linkage. Cadernos de Saúde Pública. 2000; Rio de Janeiro, 16(2): 439-47.
Carmona L, Gómez-Reino JJ, Rodríguez- Valverde V, Pascual-Gómez DME, Mola EM, Carreño L, Figueroa M and BIOBADASER Group Effectiveness of recomendations to prevent reactivation of latente tuberculosis infection in patients treated with tumor necrosis fator antagonists. Arthritis Rheum. 2005; 52(6): 1766-72.
BiobadaBrasil. Registro da sociedade e dos reumatologistas brasileiros. Editorial. Rev Bras Reumatol. 2011; 51(2): 109-12.
BiobadaBrasil. Registro brasileiro de monitorização de terapias biológicas em doenças reumáticas. Disponível em http:// biobadaser.ser.es/biobadamerica/ Brasil/ cgi-in/upload/archivo.aspx?id=10
Farga V, Caminero JA. Tuberculosis. In: Farga V, Caminero JA. Historia Natural de la tuberculosis en la comunidad. Epidemiología. Santiago de Chile: Editorial Mediterráneo. 2011.p. 56-82.
Solovic I et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010;36(5):1185-206.
Ministério da Saúde. Secretaria de Vigilância em Saúde. Manual de Recomendações para o Controle da Tuberculose no Brasil. Brasília (DF). 2011.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2015 Vera Maria Neder Galesi, Edméa Costa Pereira, Regina Maura Cabral de Melo Abrahão, Péricles Alves Nogueira